FindTrial
Sign In

Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease

Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019958
Enrollment
Unknown
Registered
2018-12-09
Start date
2018-12-16
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Case series:Combining infliximab treatmentwith Hyperbaric Oxygen Therapy

Sponsors

Daping Hospital, Army Medical University (Third Military Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as CD based on the established criteria;and Patients willing to accept infliximab treatment; 2. Patients diagnosed as Perianal CD were confirmed by pelvic floor MRI

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed as pulmonary diseases, acute and chronic infectious diseases, heart diseases, ear and nose diseases or claustrophobia; 2. Acute abdomen or Intestinal obstruction or superior position intestinal fistula; 3. Allergic or intolerance to infliximab treatment or Hyperbaric Oxygen Therapy; 4. Patients with liver and kidney dysfunction: TBIL> 1.5 ULN, ALT or AST> 2.0 ULN, Cr> 1.5 ULN.

Design outcomes

Primary

MeasureTime frame
remission rate;—

Countries

China

Contacts

Public ContactYANG YANG

Daping Hospital, Army Medical University (Third Military Medical University)

yyang_tmmu@163.com+86 18202388902

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026